We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Too soon, too soon

11 November 2011 By Robert Cyran

Founded by the man who sold GSK his last creation for $720 mln, the firm wants to raise $50 mln. Yet it has no revenue, no drugs in trials and looks predicated on unproven science. Verastem may deserve funding – but from venture capital, not public market, investors.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)